융합 생검 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Fusion Biopsy Market size is anticipated to grow from USD 1.34 Billion in 2024 to USD 2.75 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period of 2026 to 2033.

The fusion biopsy market is experiencing significant growth, driven by advancements in imaging technologies and the increasing prevalence of prostate cancer. Fusion biopsy combines traditional ultrasound imaging with magnetic resonance imaging (MRI) to enhance the accuracy of prostate cancer diagnosis. This innovative approach allows for targeted sampling of suspicious lesions, improving the detection rate of clinically significant cancers while minimizing unnecessary biopsies. As awareness of prostate cancer rises and screening guidelines evolve, the demand for fusion biopsy procedures is expected to increase, positioning this market for robust expansion.

Moreover, the growing emphasis on personalized medicine is influencing the fusion biopsy landscape. By providing more precise information about tumor characteristics, fusion biopsy enables healthcare providers to tailor treatment plans to individual patients. This shift towards targeted therapies is particularly relevant in oncology, where understanding the specific biology of a tumor can significantly impact treatment outcomes. As healthcare systems increasingly adopt precision medicine approaches, the fusion biopsy market is likely to benefit from the integration of advanced diagnostic tools that enhance patient care and optimize resource utilization.

Additionally, the rise of minimally invasive procedures is driving the adoption of fusion biopsy techniques. Patients are increasingly seeking options that reduce discomfort and recovery time, making fusion biopsy an attractive alternative to traditional biopsy methods. The development of user-friendly devices and training programs for healthcare professionals is further facilitating the adoption of this technology. As the fusion biopsy market continues to evolve, ongoing research and innovation will play a crucial role in expanding its applications and improving diagnostic accuracy, ultimately contributing to better patient outcomes in the fight against prostate cancer.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Tech Target

• DNA
• RNA
• Protein

By Product

• Multi-gene Panels
• Single-gene Tests
• Companion Diagnostics
• Research Use Only (RUO) Kits

By Application

• Oncology
• Neurology
• Infectious Diseases
• Cardiovascular Diseases

By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Digital PCR
• NanoString Technologies
• COMPANIES PROFILED
• Hologic Inc.
• Exact Sciences Corporation
• Myriad Genetics Inc.
• BioRad Laboratories Inc.
• Invivoscribe
• Leica Biosystems
• Affymetrix Inc.
• QIAGEN N.V.
• BD (Becton
• Dickinson and Company)
• Agilent Technologies Inc.
• Genomic Health
• Sysmex Corporation
• Beckman Coulter Inc.
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. FUSION BIOPSY INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Tech Target
  • 3.7.2 Market Attractiveness Analysis By Product
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Technology
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL FUSION BIOPSY MARKET ANALYSIS BY TECH TARGET

• 5.1. Overview By Tech Target
• 5.2. Historical and Forecast Data Analysis By Tech Target
• 5.3. DNA Historic and Forecast Sales By Regions
• 5.4. RNA Historic and Forecast Sales By Regions
• 5.5. Protein Historic and Forecast Sales By Regions

6. GLOBAL FUSION BIOPSY MARKET ANALYSIS BY PRODUCT

• 6.1. Overview By Product
• 6.2. Historical and Forecast Data Analysis By Product
• 6.3. Multi-gene Panels Historic and Forecast Sales By Regions
• 6.4. Single-gene Tests Historic and Forecast Sales By Regions
• 6.5. Companion Diagnostics Historic and Forecast Sales By Regions
• 6.6. Research Use Only (RUO) Kits Historic and Forecast Sales By Regions

7. GLOBAL FUSION BIOPSY MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Oncology Historic and Forecast Sales By Regions
• 7.4. Neurology Historic and Forecast Sales By Regions
• 7.5. Infectious Diseases Historic and Forecast Sales By Regions
• 7.6. Cardiovascular Diseases Historic and Forecast Sales By Regions

8. GLOBAL FUSION BIOPSY MARKET ANALYSIS BY TECHNOLOGY

• 8.1. Overview By Technology
• 8.2. Historical and Forecast Data Analysis By Technology
• 8.3. Next-Generation Sequencing (NGS) Historic and Forecast Sales By Regions
• 8.4. Polymerase Chain Reaction (PCR) Historic and Forecast Sales By Regions
• 8.5. Digital PCR Historic and Forecast Sales By Regions
• 8.6. NanoString Technologies Historic and Forecast Sales By Regions

9. GLOBAL FUSION BIOPSY MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE FUSION BIOPSY COMPANIES

• 10.1. Fusion Biopsy Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF FUSION BIOPSY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Hologic Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Exact Sciences Corporation
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Myriad Genetics Inc.
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. BioRad Laboratories Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Invivoscribe
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Leica Biosystems
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Affymetrix Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Qiagen N.V.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. BD (Becton
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Dickinson And Company)
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Agilent Technologies Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Genomic Health
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Sysmex Corporation
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Beckman Coulter Inc.
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments
• 11.17. Thermo Fisher Scientific Inc.
  • 11.17.1 Company Overview
  • 11.17.2 Company Revenue
  • 11.17.3 Products
  • 11.17.4 Recent Developments
• 11.18. Illumina Inc
  • 11.18.1 Company Overview
  • 11.18.2 Company Revenue
  • 11.18.3 Products
  • 11.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies